Pharma giant Lupin Ltd. announced that it has teamed up with Honeywell to develop next-generation inhalers using the latter's propellant, "Solstice Air," to revolutionize respiratory care.
“Lupin’s partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide”, says Vinita Gupta, CEO Lupin.
“By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact,” adds Vinita.
Honeywell's 'Solstice Air', which is intended for people with asthma and chronic obstructive pulmonary disease (COPD), has the ability to stop the production of chemicals with a high global warming potential (GWP), which would be a significant step in lowering carbon emissions, according to the company.
As a next-generation propellant for pressurized metered-dose inhalers (pMDIs), Lupin stated that it plans to be the first pharmaceutical business in India to adopt Honeywell's Solstice Air product on a large scale.
“Solstice Air can play a critical role in ensuring that Lupin’s respiratory inhalers provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions,” says Ashish Modi, President, Honeywell India.
“By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions reducing practices that support industry advancements.”
It further stated that Solstice Air provides a substitute for conventional propellants based on hydrofluorocarbons (HFCs), assisting in a 99.9 percent reduction in greenhouse gas emissions.
Also Read: Nutritious Food for All: Less Explored Paths Leaders Should Focus On
It further stated that the conditions of the agreement are contingent upon the negotiation and execution of final documents that are agreeable to both Honeywell and Lupin.